Eli Lilly and Company (LLY · NYSE)
LLY · MARKET VIEW
Market view · as of Jun 8, 2026
Revenue (TTM)
$72.25B
+55.5% YoY
Gross margin
82.8%
EPS (latest q)
$8.55
vs $6.79 est · beat
52-wk position
100.0%
0.0% vs 52w high · +16.2% 1mo
Price (last ~year)
Eli Lilly and Company, currently valued at $1.01 trillion, recently reported that its experimental obesity drug retatrutide demonstrated significant efficacy in reducing sleep apnea and osteoarthritis pain. The pharmaceutical firm continues to show strong momentum, with first-quarter 2026 revenue of $19.80 billion marking a 55.5% year-over-year increase alongside a 169.9% rise in earnings. With a profit margin of 35.0%, the stock is trading at $1131.42, reflecting a 16.2% gain over the past month.
Valuation
- Market cap
- $1.01T
- P/E
- 40.16
- PEG
- 1.517
- P/B
- 32.34
- P/S
- 13.96
- EV/EBITDA
- 28.91
- Beta
- 0.517
- Analyst target
- $1215.1
Quality & returns
- Gross margin
- 82.8%
- Operating margin
- 49.4%
- Profit margin
- 35.0%
- ROE
- 107.5%
- ROA
- 20.7%
Price movement
- Last
- $1131.42
- 1-month
- +16.2%
- 3-month
- +13.4%
- RSI (14)
- 72
- vs SMA200
- +19.7%
- 52-wk position
- 100.0% 0.0% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $19.80B | $8.85B | $7.40B | $9.36B |
| 2025-12-31 | $19.29B | $8.78B | $6.64B | $8.39B |
| 2025-09-30 | $17.60B | $8.39B | $5.58B | $7.88B |
| 2025-06-30 | $15.56B | $7.13B | $5.66B | $7.50B |
Recent news
- Somewhat-Bullish CVS Health Corporation $CVS Shares Sold by Brandywine Global Investment Management LLC · 2026-06-08
- Somewhat-Bullish Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics · 2026-06-07
- Somewhat-Bullish Los Angeles Capital Management LLC Sells 676,504 Shares of Gilead Sciences, Inc. $GILD · 2026-06-07
- Somewhat-Bullish Capital World Investors Acquires 3,095,167 Shares of Restaurant Brands International Inc. $QSR · 2026-06-07
- Bullish Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits · 2026-06-06
- Bullish Dexcom G7 gave Type 2 adults 5 extra hours a day in range · 2026-06-06
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)